Randomised controlled trial of arthrocentesis with or without PRF for internal derangement of the TMJ

This prospective randomised clinical study aims to evaluate different treatments in patients with temporomandibular disorder. Control group (C) patients underwent arthrocentesis and experimental group (E) patients underwent injectable platelet-rich fibrin (İ-PRF) in addition to arthrocentesis. Helkimo Clinical Dysfunction Score (HCDS) examinations and VAS scores of the patients were recorded at the end of the 10th day, 1 month and 3 months. 36 patients (17 females, 19 males), 18 in the experimental and 18 in the control group, aged between 18 and 64 years and in groups 3, 4 and 5 according to Wilke's classification were included in this study. Improvement of VAS (E mean: 5,83, E standard deviation: 2,550, C mean: 2,94, C standard deviation: 2,043, p<0.001) and HCDS (E mean: 13,61, E standard deviation: 5,158, C mean: 9,22, C standard deviation: 6,916, p:0.039) of the experimental group patients was significantly higher than control group at the end of the third month. As a result of this study, the combination of i-PRF with arthrocentesis gave a much better outcome than arthrocentesis alone. Additional PRF injection should be preferred for severe dysfunction. Further studies with long-term follow-up are needed to better understand the effects of i-PRF.